L-Polaflux

Levomethadone Hydrochloride, the active ingredient in L-Polaflux, is an opioid analgesic presented as an oral formulation for oral use. It is employed in the management of opioid dependence and chronic pain in adult patients, providing withdrawal symptom control and analgesia.

GNH USA supplies L-Polaflux as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across global markets. The company adheres to EU GMP standards and provides comprehensive logistics support for timely delivery to its clients.

Levomethadone Hydrochloride is used in opioid‑related disorders and pain management, acting on the central opioid system.

- Opioid dependence: helps reduce withdrawal symptoms and supports maintenance therapy in patients undergoing opioid substitution. - Chronic pain: provides analgesic effect for persistent moderate to severe pain when other treatments are insufficient. - Opioid withdrawal management: facilitates safe tapering by alleviating acute withdrawal signs during detoxification programs.

Levomethadone Hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Constipation: reduced bowel movements. - Drowsiness: increased sleepiness or fatigue. - Dizziness: light‑headed sensation. - Sweating: excessive perspiration. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, potentially life‑threatening. - Cardiac arrhythmia: abnormal heart rhythm, including QT prolongation. - Seizures: convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Levomethadone Hydrochloride, clinicians should observe several safety precautions.

- Assess patient history: evaluate prior opioid use, dependence risk, and respiratory conditions. - Monitor cardiac function: baseline ECG and periodic QT interval checks are recommended. - Adjust dose in renal/hepatic impairment: reduce dosage for patients with compromised liver or kidney function. - Avoid concurrent CNS depressants: limit use with benzodiazepines, alcohol, or other sedatives. - Counsel on driving: advise patients about possible drowsiness and impaired coordination. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Levomethadone Hydrochloride interacts with several medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Other opioid agonists: additive respiratory depression and sedation. - QT‑prolonging agents: increased risk of cardiac arrhythmia (e.g., certain antiarrhythmics, macrolide antibiotics). - CNS depressants: heightened sedation and respiratory compromise (e.g., benzodiazepines, barbiturates).

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: may raise levomethadone levels (e.g., ketoconazole, erythromycin). - CYP3A4 inducers: may reduce drug exposure (e.g., rifampin, carbamazepine). - Antidepressants: potential for serotonin syndrome when combined with serotonergic agents.